Our data show that strategies that decrease AR signaling, either through AR antagonists already FDA-approved for prostate cancer treatment [enzalutamide, apalutamide, darolutamide (30)], AR degraders [ARD-61 (28)], or castration, can lead to dose-dependent decreases in TMPRSS2 and ACE2 expression and attenuate SARS-CoV-2 infectivity. Here, AR is linked to prostate carcinoma.